To the editor: We have shown that it is feasible to administer a first-generation tyrosine kinase inhibitor (TKI) early after allogeneic hematopoietic cell transplantation (HCT) in patients with Philadelphia chromosome-positive (Ph+) leukemia.[1][1] The European Society for Blood and Marrow
No takes yet. Share an insight, caveat, or question.
Carpenter et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: